{"id":1699,"date":"2018-05-15T22:32:44","date_gmt":"2018-05-15T22:32:44","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/?p=1699"},"modified":"2018-06-04T09:30:22","modified_gmt":"2018-06-04T09:30:22","slug":"the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/","title":{"rendered":"Weight loss drugs effects on CVD remains unproven."},"content":{"rendered":"<p>&nbsp;<\/p>\n<p><em>Approved weight-loss medications have only modest effects on cardiovascular risk.<\/em><\/p>\n<p style=\"text-align: right\">Igho Onakpoya<\/p>\n<hr \/>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-thumbnail wp-image-1543 alignleft\" src=\"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/11\/index-150x150.jpg\" alt=\"\" width=\"150\" height=\"150\" srcset=\"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/11\/index-150x150.jpg 150w, https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/11\/index.jpg 225w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/>One rationale for the development and marketing of weight loss drugs is that their use will improve cardiac risk factors. In a recent systematic review and network meta-analysis [<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29305933\">1<\/a>]\u00a0 of 28 randomised controlled trials (29,018 participants), the authors concluded that the effects of weight loss drugs in improving cardiometabolic risk was modest at best. This pales into insignificance when compared with bariatric surgery for example that has been shown to improve cardiometabolic profile, and thus reduce the risk of adverse cardiovascular events [<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3962512\/\">2<\/a>].<\/p>\n<p>A flaw in the report is that adverse events were not assessed; however, the authors reported that the trials had high drop-out rates, and noted that the trials did not last beyond 12 months.<\/p>\n<p>The clinical effectiveness of any intervention in clinical practice should be based on the benefit-to-harm balance. We have previously shown that the use of centrally-acting weight loss drugs in particular significantly increase the risk of nervous, psychiatric, gastrointestinal adverse events [<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29399971\">3<\/a>]; this finding was no different when we compared withdrawn drugs to those presently on the marketed. While head-to-head comparisons of weight loss drugs provide insight into their potential comparative advantages, such comparisons should be assessed on the reporting\u00a0of both benefit and harms.<\/p>\n<hr \/>\n<p><em> Igho J. Onakpoya is a Physician and Research Fellow at the Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford and Research editor\u00a0BMJ Evidence-Based Medicine<\/em><\/p>\n<p>Competing interests: None declared<\/p>\n<p>References<\/p>\n<p class=\"title\"><span style=\"font-size: 1rem\">Khera R, Pandey A,\u00a0<\/span>Chandar<span style=\"font-size: 1rem\">\u00a0AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S.\u00a0<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29305933\">Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.\u00a0<\/a><span class=\"jrnl\" style=\"font-size: 1rem\" title=\"Gastroenterology\">Gastroenterology<\/span><span style=\"font-size: 1rem\">. 2018 Apr;154(5):1309-1319.e7. doi: 10.1053\/j.gastro.2017.12.024.<\/span><\/p>\n<p><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Approved weight-loss medications have only modest effects on cardiovascular risk. Igho Onakpoya One rationale for the development and marketing of weight loss drugs is that their use will improve cardiac risk factors. In a recent systematic review and network meta-analysis [1]\u00a0 of 28 randomised controlled trials (29,018 participants), the authors concluded that the effects [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":1464,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14373,14383],"tags":[],"class_list":["post-1699","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-synthesis","category-igho-onakpoya"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Weight loss drugs effects on CVD remains unproven. - BMJ EBM Spotlight<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Weight loss drugs effects on CVD remains unproven. - BMJ EBM Spotlight\" \/>\n<meta property=\"og:description\" content=\"&nbsp; Approved weight-loss medications have only modest effects on cardiovascular risk. Igho Onakpoya One rationale for the development and marketing of weight loss drugs is that their use will improve cardiac risk factors. In a recent systematic review and network meta-analysis [1]\u00a0 of 28 randomised controlled trials (29,018 participants), the authors concluded that the effects [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/\" \/>\n<meta property=\"og:site_name\" content=\"BMJ EBM Spotlight\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-15T22:32:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-06-04T09:30:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/10\/image-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"380\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"Weight loss drugs effects on CVD remains unproven.\",\"datePublished\":\"2018-05-15T22:32:44+00:00\",\"dateModified\":\"2018-06-04T09:30:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/\"},\"wordCount\":291,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/files\\\/2017\\\/10\\\/image-4.jpg\",\"articleSection\":[\"Evidence Synthesis\",\"Igho Onakpoya\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/\",\"name\":\"Weight loss drugs effects on CVD remains unproven. - BMJ EBM Spotlight\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/files\\\/2017\\\/10\\\/image-4.jpg\",\"datePublished\":\"2018-05-15T22:32:44+00:00\",\"dateModified\":\"2018-06-04T09:30:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/files\\\/2017\\\/10\\\/image-4.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/files\\\/2017\\\/10\\\/image-4.jpg\",\"width\":380,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/2018\\\/05\\\/15\\\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Weight loss drugs effects on CVD remains unproven.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/\",\"name\":\"BMJ EBM Spotlight\",\"description\":\"The new blog for the journal BMJ Evidence-Based Medicine, edited by Carl Heneghan\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/#organization\",\"name\":\"BMJ EBM Spotlight\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/files\\\/2017\\\/10\\\/admin-ajax.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/files\\\/2017\\\/10\\\/admin-ajax.png\",\"width\":300,\"height\":34,\"caption\":\"BMJ EBM Spotlight\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmjebmspotlight\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Weight loss drugs effects on CVD remains unproven. - BMJ EBM Spotlight","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/","og_locale":"en_GB","og_type":"article","og_title":"Weight loss drugs effects on CVD remains unproven. - BMJ EBM Spotlight","og_description":"&nbsp; Approved weight-loss medications have only modest effects on cardiovascular risk. Igho Onakpoya One rationale for the development and marketing of weight loss drugs is that their use will improve cardiac risk factors. In a recent systematic review and network meta-analysis [1]\u00a0 of 28 randomised controlled trials (29,018 participants), the authors concluded that the effects [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/","og_site_name":"BMJ EBM Spotlight","article_published_time":"2018-05-15T22:32:44+00:00","article_modified_time":"2018-06-04T09:30:22+00:00","og_image":[{"width":380,"height":250,"url":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/10\/image-4.jpg","type":"image\/jpeg"}],"author":"BMJ","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BMJ","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"Weight loss drugs effects on CVD remains unproven.","datePublished":"2018-05-15T22:32:44+00:00","dateModified":"2018-06-04T09:30:22+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/"},"wordCount":291,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/10\/image-4.jpg","articleSection":["Evidence Synthesis","Igho Onakpoya"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/","url":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/","name":"Weight loss drugs effects on CVD remains unproven. - BMJ EBM Spotlight","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/10\/image-4.jpg","datePublished":"2018-05-15T22:32:44+00:00","dateModified":"2018-06-04T09:30:22+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/#primaryimage","url":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/10\/image-4.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/10\/image-4.jpg","width":380,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/2018\/05\/15\/the-benefits-of-weight-loss-drugs-on-cardiometabolic-profile-remains-unproven\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/"},{"@type":"ListItem","position":2,"name":"Weight loss drugs effects on CVD remains unproven."}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/#website","url":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/","name":"BMJ EBM Spotlight","description":"The new blog for the journal BMJ Evidence-Based Medicine, edited by Carl Heneghan","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/#organization","name":"BMJ EBM Spotlight","url":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/10\/admin-ajax.png","contentUrl":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/files\/2017\/10\/admin-ajax.png","width":300,"height":34,"caption":"BMJ EBM Spotlight"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/1699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=1699"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/1699\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media\/1464"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=1699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=1699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=1699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}